Inspire Semiconductor Holdings Inc is engaged in developing the Thunderbird Accelerated Computing Solution which is based on an array of thousands of processor cores, with an interconnection network, and is compatible with an established software ecosystem.
Clinical Trials
13
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2007
Active, not recruiting
2
15.4%
Completed
4
30.8%
Recruiting
4
30.8%
Terminated
1
7.7%
Unknown
2
15.4%
No approval data available
- Nyxoah filed a patent infringement lawsuit against Inspire Medical Systems in Delaware federal court, alleging that Inspire's IV and V devices infringe three of Nyxoah's patents. - The lawsuit seeks injunctive relief and damages, as Nyxoah defends its intellectual property portfolio for the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. - Nyxoah's Genio system received FDA approval in August 2025 and offers differentiated features including bilateral stimulation, full body MRI compatibility, and an upgradable platform without requiring re-surgery for battery replacements. - The company reports positive feedback from physicians and patients in the first month following its U.S. commercial launch of the Genio system.
- Livanova's aura6000 hypoglossal nerve stimulator met primary safety and efficacy endpoints in a randomized trial for obstructive sleep apnea (OSA). - The trial demonstrated improvements in OSA severity and blood oxygen levels after six months of treatment with the aura6000 device. - Livanova plans to file for premarket approval with the FDA after completing data analysis from the seven-month follow-up visits. - Analysts suggest that while the data looks promising, Livanova may face challenges entering the competitive sleep apnea market.
- Phelps Health now offers Inspire therapy, an FDA-approved treatment for obstructive sleep apnea (OSA) for those struggling with CPAP. - Inspire therapy uses mild stimulation to open the airway during sleep, improving oxygen flow and sleep quality. - The STAR clinical trial demonstrated significant reductions in sleep apnea events and improvements in quality-of-life measures with Inspire. - Inspire therapy represents a significant advancement in treating sleep apnea, offering a mask-free, hose-free alternative to CPAP.
